Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS

Renaissance Technologies LLC acquired a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 81,310 shares of the company’s stock, valued at approximately $1,190,000.

A number of other large investors have also recently bought and sold shares of CRVS. Mirae Asset Global Investments Co. Ltd. increased its position in Corvus Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock worth $28,000 after buying an additional 748 shares during the last quarter. ProShare Advisors LLC lifted its position in shares of Corvus Pharmaceuticals by 7.7% in the fourth quarter. ProShare Advisors LLC now owns 13,764 shares of the company’s stock worth $106,000 after buying an additional 979 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Corvus Pharmaceuticals by 5.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 34,105 shares of the company’s stock worth $263,000 after buying an additional 1,696 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Corvus Pharmaceuticals by 6.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 32,232 shares of the company’s stock worth $238,000 after acquiring an additional 1,812 shares in the last quarter. Finally, Shelton Wealth Management LLC boosted its stake in shares of Corvus Pharmaceuticals by 13.8% during the 4th quarter. Shelton Wealth Management LLC now owns 15,638 shares of the company’s stock worth $120,000 after acquiring an additional 1,896 shares in the last quarter. 46.64% of the stock is currently owned by institutional investors.

Key Stories Impacting Corvus Pharmaceuticals

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: An independent analysis examines soquelitinib’s clinical science, commercial market opportunity and fair value, keeping attention focused on the potential upside from Corvus’s lead program. The stock has increased from its 52-week low, suggesting investors continue to assign meaningful value to the drug’s development prospects. Corvus: Evaluating Soquelitinib’s Science, Market Reach, And Fair Value
• Neutral Sentiment: HC Wainwright issued a new FY2030 earnings forecast for Corvus. The article does not provide the estimate, but the long-range projection indicates analysts are continuing to model the company’s path toward commercialization and profitability. FY2030 Earnings Forecast for CRVS Issued By HC Wainwright
• Negative Sentiment: HC Wainwright lowered EPS estimates across multiple periods: FY2026 to a loss of $0.83 from $0.66, FY2027 to a loss of $0.80 from $0.63, FY2028 to a loss of $0.37 from $0.25, and FY2029 to a loss of $0.01 from a profit of $0.07. Quarterly estimates were also reduced, including Q3 2026 to a loss of $0.23 from $0.17 and Q1–Q4 2027 to losses ranging from $0.16 to $0.24 per share. These revisions imply slower progress toward profitability and could pressure sentiment. HC Wainwright Earnings Estimate Revisions for Corvus Pharmaceuticals

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CRVS. Weiss Ratings raised Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. LADENBURG THALM/SH SH raised Corvus Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, July 30th. Wall Street Zen lowered shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, The Goldman Sachs Group started coverage on shares of Corvus Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $40.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $33.33.

Insider Activity at Corvus Pharmaceuticals

In other news, Director David Scott Moore bought 21,700 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average cost of $11.53 per share, with a total value of $250,201.00. Following the completion of the transaction, the director directly owned 21,700 shares in the company, valued at $250,201. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 19.70% of the company’s stock.

Corvus Pharmaceuticals Stock Performance

NASDAQ:CRVS opened at $15.14 on Friday. Corvus Pharmaceuticals, Inc. has a 52-week low of $4.70 and a 52-week high of $26.95. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -24.82 and a beta of 0.87. The firm’s 50-day moving average is $13.64 and its 200-day moving average is $15.14.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). Equities analysts predict that Corvus Pharmaceuticals, Inc. will post -0.79 EPS for the current year.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.